151 related articles for article (PubMed ID: 37195148)
21. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma.
Chen H; Nio K; Yamashita T; Okada H; Li R; Suda T; Li Y; Doan PTB; Seki A; Nakagawa H; Toyama T; Terashima T; Iida N; Shimakami T; Takatori H; Kawaguchi K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
Mol Oncol; 2021 Aug; 15(8):2203-2218. PubMed ID: 33834612
[TBL] [Abstract][Full Text] [Related]
22. Comparative analysis of TGF-β/Smad signaling dependent cytostasis in human hepatocellular carcinoma cell lines.
Dzieran J; Fabian J; Feng T; Coulouarn C; Ilkavets I; Kyselova A; Breuhahn K; Dooley S; Meindl-Beinker NM
PLoS One; 2013; 8(8):e72252. PubMed ID: 23991075
[TBL] [Abstract][Full Text] [Related]
23. Snail mediates crosstalk between TGFβ and LXRα in hepatocellular carcinoma.
Bellomo C; Caja L; Fabregat I; Mikulits W; Kardassis D; Heldin CH; Moustakas A
Cell Death Differ; 2018 May; 25(5):885-903. PubMed ID: 29230000
[TBL] [Abstract][Full Text] [Related]
24. Bioinformatics Analysis Identifies Protein Tyrosine Kinase 7 (PTK7) as a Potential Prognostic and Therapeutic Biomarker in Stages I to IV Hepatocellular Carcinoma.
Zou RC; Liang Y; Li LL; Tang JZ; Yang YP; Geng YC; He J; Luo LY; Li WX; Sun ZW; Yuan HL
Med Sci Monit; 2019 Nov; 25():8618-8627. PubMed ID: 31730575
[TBL] [Abstract][Full Text] [Related]
25. The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma.
Ahn SM; Haq F; Park I; Nault JC; Zucman-Rossi J; Yu E
BMC Cancer; 2018 May; 18(1):571. PubMed ID: 29776391
[TBL] [Abstract][Full Text] [Related]
26. EYA4 inhibits hepatocellular carcinoma growth and invasion by suppressing NF-κB-dependent RAP1 transactivation.
Mo SJ; Hou X; Hao XY; Cai JP; Liu X; Chen W; Chen D; Yin XY
Cancer Commun (Lond); 2018 Apr; 38(1):9. PubMed ID: 29764501
[TBL] [Abstract][Full Text] [Related]
27. HIF-1α promoted vasculogenic mimicry formation in hepatocellular carcinoma through LOXL2 up-regulation in hypoxic tumor microenvironment.
Wang M; Zhao X; Zhu D; Liu T; Liang X; Liu F; Zhang Y; Dong X; Sun B
J Exp Clin Cancer Res; 2017 Apr; 36(1):60. PubMed ID: 28449718
[TBL] [Abstract][Full Text] [Related]
28. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
29. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation.
Lai SC; Su YT; Chi CC; Kuo YC; Lee KF; Wu YC; Lan PC; Yang MH; Chang TS; Huang YH
J Exp Clin Cancer Res; 2019 Nov; 38(1):474. PubMed ID: 31771617
[TBL] [Abstract][Full Text] [Related]
30. Computational Analysis of Transcriptomic and Proteomic Data for Deciphering Molecular Heterogeneity and Drug Responsiveness in Model Human Hepatocellular Carcinoma Cell Lines.
Agioutantis PC; Loutrari H; Kolisis FN
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32517019
[TBL] [Abstract][Full Text] [Related]
31. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity.
Liu ZH; Lian BF; Dong QZ; Sun H; Wei JW; Sheng YY; Li W; Li YX; Xie L; Liu L; Qin LX
Biochim Biophys Acta Mol Basis Dis; 2018 Jun; 1864(6 Pt B):2360-2368. PubMed ID: 29408647
[TBL] [Abstract][Full Text] [Related]
32. Induction of Chromosome Instability by Activation of Yes-Associated Protein and Forkhead Box M1 in Liver Cancer.
Weiler SME; Pinna F; Wolf T; Lutz T; Geldiyev A; Sticht C; Knaub M; Thomann S; Bissinger M; Wan S; Rössler S; Becker D; Gretz N; Lang H; Bergmann F; Ustiyan V; Kalin TV; Singer S; Lee JS; Marquardt JU; Schirmacher P; Kalinichenko VV; Breuhahn K
Gastroenterology; 2017 Jun; 152(8):2037-2051.e22. PubMed ID: 28249813
[TBL] [Abstract][Full Text] [Related]
33. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
[TBL] [Abstract][Full Text] [Related]
34. Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.
Kowalik MA; Puliga E; Cabras L; Sulas P; Petrelli A; Perra A; Ledda-Columbano GM; Morandi A; Merlin S; Orrù C; Sanchez-Martin C; Fornari F; Gramantieri L; Parri M; Rasola A; Bellomo SE; Sebastian C; Follenzi A; Giordano S; Columbano A
J Hepatol; 2020 Jun; 72(6):1159-1169. PubMed ID: 31954205
[TBL] [Abstract][Full Text] [Related]
35. Fibronectin plays a major role in hypoxia-induced lenvatinib resistance in hepatocellular carcinoma PLC/PRF/5 cells.
Takahashi M; Okada K; Ouch R; Konno T; Usui K; Suzuki H; Satoh M; Kogure T; Satoh K; Watanabe Y; Nakamura H; Murai Y
Pharmazie; 2021 Dec; 76(12):594-601. PubMed ID: 34986955
[TBL] [Abstract][Full Text] [Related]
36. Identification of survival-related predictors in hepatocellular carcinoma through integrated genomic, transcriptomic, and proteomic analyses.
Dong F; Yang Q; Wu Z; Hu X; Shi D; Feng M; Li J; Zhu L; Jiang S; Bao Z
Biomed Pharmacother; 2019 Jun; 114():108856. PubMed ID: 30981109
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling.
Wang JL; Yang MY; Xiao S; Sun B; Li YM; Yang LY
J Exp Clin Cancer Res; 2018 Mar; 37(1):45. PubMed ID: 29506567
[TBL] [Abstract][Full Text] [Related]
38. TGFβ overrides HNF4α tumor suppressing activity through GSK3β inactivation: implication for hepatocellular carcinoma gene therapy.
Cozzolino AM; Alonzi T; Santangelo L; Mancone C; Conti B; Steindler C; Musone M; Cicchini C; Tripodi M; Marchetti A
J Hepatol; 2013 Jan; 58(1):65-72. PubMed ID: 22960426
[TBL] [Abstract][Full Text] [Related]
39. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Biomarker Identification Through Integrating the Gene Signatures of Hepatocellular Carcinoma Properties.
Cai J; Li B; Zhu Y; Fang X; Zhu M; Wang M; Liu S; Jiang X; Zheng J; Zhang X; Chen P
EBioMedicine; 2017 May; 19():18-30. PubMed ID: 28434945
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
